Trial results for new lung cancer drug are ‘off the charts’, say doctors
www.theguardian.com
More than half of patients with advanced forms of disease who took lorlatinib were still alive after five years with no progression
  • @will_a113@lemmy.ml
    3•7 months ago

    New drug: 60% survival rate with no disease progression.

    Current-best drug: 8%

    While technically it’s not “off the charts”, this is pretty damn impressive. I’ll allow the hyperbole.